Filter Results:
(446)
Show Results For
- All HBS Web
(632)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(632)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Sort by
- 01 May 2009
- Conference Presentation
The enabling and constraining effects of attention structures on entrepreneurial activity in the U.S. biodiesel industry
By: Shon R. Hiatt
- February 2010
- Background Note
Millipore Background Note
By: Elie Ofek and Natalie Kindred
This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details
Keywords: Organizational Change and Adaptation; Customer Focus and Relationships; Biotechnology Industry; Biotechnology Industry
Ofek, Elie, and Natalie Kindred. "Millipore Background Note." Harvard Business School Background Note 510-059, February 2010.
- July 2009
- Teaching Note
Khosla Ventures: Biofuels Strategy (TN)
Teaching Note for [809004]. View Details
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Biotechnology Industry; Biotechnology Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Biotechnology Industry; Biotechnology Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Biotechnology Industry; Biotechnology Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 20 May 2013
- Op-Ed
Making America an Industrial Powerhouse Again
computer science, optics, and various engineering disciplines. We need to get over the outdated notion that manufacturing is "mature" and unconnected to science. Anyone who believes that should take a tour of a factory that produces semiconductors or View Details
- 15 Feb 2000
- Research & Ideas
The Right Connections
of IPO Team Ties on Investment Bank Affiliation and IPO Success," which examines how individuals' affiliations can affect the formation of alliances at the firm level. To that end, the researchers pinpointed the biotechnology... View Details
Keywords: by Judith A. Ross
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
Keywords: Clusters; Economics; Industry Clusters; Economy; Growth and Development; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; San Diego
Porter, Michael E. "Clusters of Innovation Initiative: San Diego." Council on Competitiveness, Washington, DC, May 2001. (Report.)
- October 2012
- Supplement
Aqua Bounty Courseware
By: Lucy White and Steve Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details
- December 2003 (Revised April 2004)
- Case
Dragon's Teeth Vineyards
By: Alan D. MacCormack, Marius Leibold, Sven Voelpel and Kerry Herman
Dragon's Teeth Vineyards (DTV) is a South African wine producer that is considering whether to use genetically modified organisms (GMOs) in its wine-making process. GMOs promise to lower the costs of wine production significantly through increased yields and reduced... View Details
Keywords: Technological Innovation; Growth and Development Strategy; Genetics; Transition; Brands and Branding; Product Development; Product Design; Organizational Change and Adaptation; Technology Adoption; Biotechnology Industry; Biotechnology Industry; South Africa
MacCormack, Alan D., Marius Leibold, Sven Voelpel, and Kerry Herman. "Dragon's Teeth Vineyards." Harvard Business School Case 604-069, December 2003. (Revised April 2004.)
- February 1999
- Teaching Note
Pioneer Hi-Bred International, Inc.: Supply Management TN
By: Francis Aguilar, Paul Clark and Xin Xi He
Teaching Note for (9-898-238) and (9-898-239). View Details
- January 2014 (Revised June 2014)
- Supplement
23andMe: Genetic Testing for Consumers (B)
By: John A. Quelch and Margaret L. Rodriguez
Following the FDA's letter in November 2013, which ordered 23andMe to cease sales of its DNA test kits, observers wondered how co-founder and CEO, Anne Wojcicki, would guide the company in the presence of uncertainty. View Details
Keywords: Risk and Uncertainty; Genetics; Crisis Management; Health Care and Treatment; Product Development; Business and Government Relations; Biotechnology Industry; Biotechnology Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (B)." Harvard Business School Supplement 514-095, January 2014. (Revised June 2014.)
- 03 Feb 2009
- First Look
First Look: February 3, 2009
Contractibility and Contract Design in Strategic Alliances Authors: Josh Lerner and Ulrike Malmendier Publication: American Economic Review (forthcoming) Abstract We analyze how variations in contractibility affect the design of contracts in the context of View Details
Keywords: Martha Lagace
- 22 Sep 2020
- Research & Ideas
Recessions Push Some Entrepreneurs to Launch Too Soon
an associate professor at University of Lausanne, studied 3,025 US founders from 2005 to 2012 and their 1,747 startups in the biotechnology and medical device sectors during previous economic downturns. Their research was conducted before... View Details
Keywords: by Sean Silverthorne